Alnylam Pharmaceuticals' Other financing activities fell 121.24% to -$1.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $8.3 million, marking a year-over-year decrease of 65.03%. This contributed to the annual value of $24.7 million for FY2023, which is 20.43% down from last year.
Latest data reveals that Alnylam Pharmaceuticals reported Other financing activities of -$1.8 million as of Q3 2024, which was down 38.07% from -$1.3 million recorded in Q2 2024.
In the past 5 years, Alnylam Pharmaceuticals' Other financing activities ranged from a high of $8.3 million in Q4 2023 and a low of -$1.8 million during Q3 2024.
Moreover, its 3-year median value for Other financing activities was $7.5 million (2022), whereas its average is $5.1 million.
Its Other financing activities has fluctuated over the past 5 years, first spiked by 114.29% in 2022, then slumped by 132.05% in 2024.
Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Other financing activities stood at $4.2 million in 2020, then decreased by 16.67% to $3.5 million in 2021, then spiked by 114.29% to $7.5 million in 2022, then rose by 11.12% to $8.3 million in 2023, then crashed by 121.24% to -$1.8 million in 2024.
Its last three reported values are -$1.8 million in Q3 2024, -$1.3 million for Q2 2024, and $3.1 million during Q1 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value